A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2008-2010

ABSTRACT

This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin combination in patients with advanced non-squamous non-small cell lung cancer. A total of approximately 100 patients are planned to be enrolled, and following completion of four cycles of pemetrexed-cisplatin (Induction Phase) those patients in which disease progression has not occurred will be randomized in a 2:1 ratio to one of two treatment arms (Maintenance Phase): Arm A (pemetrexed plus best supportive care) or Arm B (best supportive care alone). More... »

URL

https://clinicaltrials.gov/show/NCT00606021

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin combination in patients with advanced non-squamous non-small cell lung cancer. A total of approximately 100 patients are planned to be enrolled, and following completion of four cycles of pemetrexed-cisplatin (Induction Phase) those patients in which disease progression has not occurred will be randomized in a 2:1 ratio to one of two treatment arms (Maintenance Phase): Arm A (pemetrexed plus best supportive care) or Arm B (best supportive care alone).", 
    "endDate": "2010-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00606021", 
    "keywords": [
      "BEST", 
      "supportive care", 
      "first-line treatment", 
      "patient", 
      "non small cell lung cancer", 
      "multicenter", 
      "phase study", 
      "maintenance therapy", 
      "cisplatin", 
      "completion", 
      "cycle", 
      "induction phase", 
      "disease progression", 
      "treatment arm", 
      "maintenance phase", 
      "arm"
    ], 
    "name": "A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00606021"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00004.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.417540.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2008-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1471-2407-12-423", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040693478", 
          "https://doi.org/10.1186/1471-2407-12-423"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00606021"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00606021'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00606021'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00606021'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00606021'


 

This table displays all metadata directly associated to this object as RDF triples.

39 TRIPLES      16 PREDICATES      32 URIs      25 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00606021 schema:about anzsrc-for:3142
2 schema:description This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin combination in patients with advanced non-squamous non-small cell lung cancer. A total of approximately 100 patients are planned to be enrolled, and following completion of four cycles of pemetrexed-cisplatin (Induction Phase) those patients in which disease progression has not occurred will be randomized in a 2:1 ratio to one of two treatment arms (Maintenance Phase): Arm A (pemetrexed plus best supportive care) or Arm B (best supportive care alone).
3 schema:endDate 2010-12-01T00:00:00Z
4 schema:keywords BEST
5 arm
6 cisplatin
7 completion
8 cycle
9 disease progression
10 first-line treatment
11 induction phase
12 maintenance phase
13 maintenance therapy
14 multicenter
15 non small cell lung cancer
16 patient
17 phase study
18 supportive care
19 treatment arm
20 schema:name A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
21 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00606021
22 schema:sdDatePublished 2019-03-07T15:22
23 schema:sdLicense https://scigraph.springernature.com/explorer/license/
24 schema:sdPublisher Nb257b161c0944b5284d69b57c93cf4e5
25 schema:sponsor https://www.grid.ac/institutes/grid.417540.3
26 schema:startDate 2008-01-01T00:00:00Z
27 schema:subjectOf sg:pub.10.1186/1471-2407-12-423
28 schema:url https://clinicaltrials.gov/show/NCT00606021
29 sgo:license sg:explorer/license/
30 sgo:sdDataset clinical_trials
31 rdf:type schema:MedicalStudy
32 Nb257b161c0944b5284d69b57c93cf4e5 schema:name Springer Nature - SN SciGraph project
33 rdf:type schema:Organization
34 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
35 rdf:type schema:DefinedTerm
36 sg:pub.10.1186/1471-2407-12-423 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040693478
37 https://doi.org/10.1186/1471-2407-12-423
38 rdf:type schema:CreativeWork
39 https://www.grid.ac/institutes/grid.417540.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...